FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

被引：28

作者：

Catenacci, Daniel V. T.

Kang, Yoon-Koo

Saeed, Anwaar

Yamaguchi, Kensei

Qin, Shukui

Lee, Keun-Wook

Kim, In-Ho

Oh, Sang Cheul

Li, Jin

Turk, Haci M.

Teixeira, Alexandra Carolina

Borg, Christophe

Hitre, Erika

Udrea, Anghel Adrian

Cardellino, Giovanni Gerardo

Guardeno, Raquel

Mitra, Siddhartha

Yang, Yingsi

Enzinger, Peter C.

Wainberg, Zev A.

机构：

[1] Univ Chicago, Gastrointestinal Oncol Program, Chicago, IL 60637 USA

[2] Asan Med Ctr, Seoul, South Korea

[3] Kansas Univ, Ctr Canc, Westwood, KS USA

[4] JFCR, Canc Inst Hosp, Tokyo, Japan

[5] Nanjing Univ Chinese Med, 81 Hosp, Nanjing, Peoples R China

[6] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[7] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[8] Korea Univ, Guro Hosp, Seoul, South Korea

[9] Shanghai East Hosp, Shanghai, Peoples R China

[10] Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[11] Hosp Senhora Da Oliveira, Guimaraes, Portugal

[12] Besancon Univ Hosp, Dept Med Oncol, Besancon, France

[13] Natl Inst Oncol, Dept Med Oncol & Clin Pharmacol B, Budapest, Hungary

[14] SC Medisprof SRL, Cluj Napoca, Romania

[15] Azienda Sanit Univ Friuli Cent, Dept Oncol, Udine, Italy

[16] Hosp Josep Trueta, Inst Catala Oncol, Girona, Spain

[17] Five Prime Therapeut Inc, San Francisco, CA USA

[18] Dana Farber Canc Inst, Boston, MA 02115 USA

[19] Univ Calif Los Angeles, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4010

引用

页数：2